Pricing Log in Create free account

Clene Inc. (CLNN) vs Spero Therapeutics, Inc. (SPRO)

Clene Inc. and Spero Therapeutics, Inc. are both Biotechnology companies. Clene Inc. and Spero Therapeutics, Inc. are of similar size ($63.1M and $62.3M). Clene Inc. has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 7.7×. Spero Therapeutics, Inc. grew revenue faster over the last twelve months: 37.2% against 11.2%. Spero Therapeutics, Inc. has the higher net margin (0.00% vs −11,271.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Spero Therapeutics, Inc. leads on 14 and Clene Inc. on 2.

Valuation

Metric CLNN SPRO Biotechnology median
P/E n/m 7.71 10.85
P/S 239.62 1.02 9.49
P/B n/m 1.42 2.18
Price to free cash flow n/m 3.20 25.85
EV/EBITDA n/m 1.96 0.70
EV/Sales 224.37 0.19 8.99
Earnings yield (53.92%) 12.96% (31.76%)
Free cash flow yield (29.15%) 31.21% (21.84%)

Profitability

Metric CLNN SPRO Biotechnology median
Gross margin 68.49% 100.00% 68.51%
Operating margin (8,928.57%) 0.00% 0.00%
Net margin (11,271.43%) 0.00% 0.00%
Free cash flow margin (6,984.45%) 0.00% 0.00%
Return on equity 197.50% 19.17% (50.82%)
Return on assets (120.65%) 12.85% (46.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLNN SPRO Biotechnology median
Revenue growth (TTM) 11.21% 37.24% 6.96%
EPS growth (last fiscal year) 53.26% 111.81% 29.88%
Revenue growth, 5-year CAGR (0.59%) 48.25% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLNN SPRO Biotechnology median
Debt to equity (0.42) 0.00 0.00
Current ratio 0.85 6.12 4.84
Net debt to EBITDA (0.39) (6.38) 1.01

Dividend

Metric CLNN SPRO Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric CLNN SPRO Biotechnology median
Market cap 63.07m 62.31m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack